Is cphi a good buy

China Pharma Holdings (CPHI) is not a good buy at this time. Here's why:

1. Financial Performance: The company has reported a net loss of $1.44 million and a diluted EPS of -$0.09 for the most recent quarter, indicating a loss in earnings. This is a concern as it shows that the company is not generating profits.

2. Revenue Decline: The company's revenue has declined by 15.75% year-over-year, which is a concerning trend. This decline could be indicative of underlying issues with the company's business model or market position.

3. Negative Trend in Diluted EPS: The company's diluted EPS has decreased by 28.57% quarter-over-quarter, which could suggest a negative trend in earnings.
4. Market Challenges: The company faces significant market challenges, including a highly competitive pharmaceutical industry and the need to comply with stringent regulatory requirements in China. These challenges could impact the company's financial outlook and investor confidence.
5. Average Price Target and Analyst Consensus: The company does not currently have an average price target or a consensus rating, which could indicate a lack of analyst coverage or interest.

In conclusion, the financial performance, revenue decline, and negative trend in diluted EPS suggest that CPHI is not in a strong position to make a significant investment. Investors should carefully consider these factors and monitor the company's future performance before making an investment decision.